New drug combo aims to tame advanced uterine cancer
NCT ID NCT07652515
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety of the immunotherapy drug dostarlimab when given together with standard chemotherapy (carboplatin and paclitaxel) as a first treatment for adults in India with advanced or recurrent endometrial cancer. Participants receive the drug combination initially, followed by dostarlimab alone. The main goal is to track serious side effects over about a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dostarlimab (with carboplatin and paclitaxel)
- What this could lead to
- If successful, this could confirm a safer treatment option for advanced or recurrent endometrial cancer, potentially improving outcomes for patients in India.
- What could go wrong
- This is a single-arm, open-label study with no comparison group, so results may not prove effectiveness. Side effects from the drug combination, including immune-related reactions, are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, ENDOMETRIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.